Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force

Executive Summary

Novartis plans to launch a national DTC campaign for its irritable bowel syndrome agent Zelnorm early in the third quarter, the company announced during its July 21 investor conference call
Advertisement

Related Content

Zelnorm bares its belly
Zelnorm bares its belly
FDA Objects To Novartis IBS Ads; Claims Are Zelnorm-Specific, Agency Says
Novartis’ Zelnorm Has 25% Adoption Rate Among Specialists After 2 Months
Novartis Zelnorm Approval: FDA Accepts Overseas History, Active Surveillance
Novartis Zelmac Trade Name Could Be Changed Following FDA Discussions
Novartis Zelmac Trade Name Could Be Changed Following FDA Discussions
Advertisement
UsernamePublicRestriction

Register

PS042207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel